GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.

Abstract	Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor and pro-inflammatory cytokine, plays a critical role in alveolar macrophage homeostasis, lung inflammation and immunological disease. Both administration and inhibition of GM-CSF are currently being therapeutically tested in COVID-19 clinical trials. This Perspective discusses the pleiotropic biology of GM-CSF and the scientific merits behind these contrasting approaches.
Authors	Frederick M Lang, Kevin M-C Lee, John R Teijaro, Burkhard Becher, John A Hamilton
Journal	Nature reviews. Immunology (Nat Rev Immunol) Vol. 20 Issue 8 Pg. 507-514 (08 2020) ISSN: 1474-1741 [Electronic] England
PMID	32576980 (Publication Type: Journal Article, Review)
Chemical References	Granulocyte-Macrophage Colony-Stimulating Factor
Topics	Betacoronavirus (drug effects) COVID-19 Clinical Trials as Topic Coronavirus Infections (drug therapy) Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use) Humans Pandemics Pneumonia, Viral (drug therapy) SARS-CoV-2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!